Gynecologic oncology in 2024: breakthrough trials and evolving treatment strategies for cervical, uterine corpus, and ovarian cancers
  • Lee, Sung Jong
  • Yoo, Ji Geun
  • Kim, Jin Hwi
  • Park, Jeong-Yeol
  • Lee, Jung-Yun
  • ... Lee, Yoo-Young
  • 외 1명
Citations

WEB OF SCIENCE

7
Citations

SCOPUS

11

초록

This review summarized the results of clinical trials in 2024 that were believed to have a significant impact on clinical practice in the field of gynecologic oncology. The SHAPE trial, INTERLACE and KEYNOTE-A18 trials, and BEATcc and COMPASSION-16 trials were included in early-stage, locally advanced, and recurrent/metastatic cervical cancer, respectively. For uterine corpus cancer, updated survival data of the four trials (NRG-GY018, RUBY, AtTEnd, DUO-E) for endometrial cancer and the first survival data of LMS-04 trial for leiomyosarcoma were described. For ovarian cancer, the final overall survival results of PRIMA study were followed by DUO-O, ATHENA-combo, and FIRST-ENGOT-OV44 trial in different disease conditions. Finally, the results of DESTINY-PanTumor02, a basket trial of trastuzumab deruxtecan, were briefly addressed.

키워드

Gynecologic NeoplasmsImmunotherapyMolecular Targeted TherapyPoly(ADP-Ribose) Polymerase InhibitorImmunoconjugatesCHEMOTHERAPYWOMEN
제목
Gynecologic oncology in 2024: breakthrough trials and evolving treatment strategies for cervical, uterine corpus, and ovarian cancers
저자
Lee, Sung JongYoo, Ji GeunKim, Jin HwiPark, Jeong-YeolLee, Jung-YunLee, Yoo-YoungSuh, Dong Hoon
DOI
10.3802/jgo.2025.36.e72
발행일
2025-01
유형
Article
저널명
Journal of Gynecologic Oncology
36
1
페이지
1 ~ 15